Relay Therapeutics, Inc.RLAYNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 100% recommend buying.

Consensus Rating

Buy

14 analysts·Moderate coverage

100%

Rating Distribution

Strong Buy

17%

Buy

1393%

Hold

00%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 65% higher.

Bear Case

$13.00

+59%

Consensus

$13.50

+65%

Bull Case

$14.00

+71%

Price Range14 analysts

Low

Consensus

High

$13.00

$14.00

Current Target

Current Price

$8.19

Upside to Target

$5.31

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-1.67(7 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+215.33%

EPS—

FY2028

Rev-15.51%

EPS—

FY2029

Rev+274.20%

EPS—

Earnings Surprises

Beat rate:75%(9/12 quarters)

Avg surprise:+10.2%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jan 26, 2026Oppenheimer

Relay Therapeutics upgraded to Outperform from Perform at Oppenheimer

Target:$14.00

+88.4%from $7.43

Dec 12, 2025Wells Fargo

Relay Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo

Target:$13.00

+66.7%from $7.80

Sep 16, 2024H.C. Wainwright

Relay Therapeutics (RLAY) PT Raised to $19 at H.C. Wainwright

Target:$19.00

+150.0%from $7.60

Sep 10, 2024Jefferies

Relay Therapeutics upgraded to Buy from Hold at Jefferies

Target:$16.00

+68.2%from $9.51

Sep 9, 2024Barclays

Relay Therapeutics price target raised to $17 from $14 at Barclays

Target:$17.00

+78.8%from $9.51

Sep 4, 2024Bank of America Securities

Relay Therapeutics (RLAY) PT Lowered to $20 at BofA Securities

Target:$20.00

+212.0%from $6.41

May 10, 2024Barclays

Barclays Upgrades Relay Therapeutics (RLAY) to Overweight

Target:$15.00

+124.7%from $6.68

May 6, 2024Oppenheimer

Relay Therapeutics (RLAY) PT Lowered to $25 at Oppenheimer

Target:$25.00

+255.1%from $7.04

Apr 20, 2023Jefferies

Jefferies Upgrades Relay Therapeutics (RLAY ) to Hold

Target:$12.50

+1.2%from $12.35

Feb 3, 2023Oppenheimer

Oppenheimer Initiates Coverage On Relay Therapeutics with Outperform Rating, Announces Price Target of $33

Target:$33.00

+45.0%from $22.76

Sep 30, 2022Barclays

Relay Therapeutics initiated with an Equal Weight at Barclays

Target:$23.00

-0.6%from $23.14

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance